SCHEMBL4540200

SCHEMBL4540200

CC(C)=CCCC(C)=CCc1cc2ccccc2oc1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VKORC1 Q9BQB6 2/20 0.60
ALOX15 P16050 5/20 0.48
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
ADAM17 P78536 1/20 0.47
MAPT P10636 2/20 0.45
MAPK1 P28482 2/20 0.45
PGR P06401 1/20 0.45
HTR1A P08908 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
PTGS1 P23219 1/20 0.45
PDE4A P27815 1/20 0.45
DRD3 P35462 1/20 0.45
SNCA P37840 1/20 0.45
PDE3A Q14432 1/20 0.45
MAOB P27338 4/20 0.45
MAOA P21397 2/20 0.45
ACHE P22303 2/20 0.45
BCHE P06276 2/20 0.45
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4540197 1.00 VKORC1 (0.60) VKORC1ALOX15MMP2MMP9ADAM17
SCHEMBL15558092 0.88 VKORC1 (0.54) VKORC1MMP2MMP9ADAM17MAOB
SCHEMBL16768172 0.76 VKORC1 (0.97) VKORC1ALOX15MAPK1MAOACYP1A2
Ostruthin SCHEMBL2936121 0.76 CA12 (0.74) ALOX15MAPTMAPK1PTGS1ACHE
Ostruthin SCHEMBL2936116 0.76 CA12 (0.74) ALOX15MAPTMAPK1PTGS1ACHE
SCHEMBL5309695 0.75 VKORC1 (1.00) VKORC1ALOX15MAPK1MAOACYP1A2
SCHEMBL5309688 0.75 VKORC1 (1.00) VKORC1ALOX15MAPK1MAOACYP1A2
SCHEMBL28561455 0.74 BACE1 (0.54) ALOX15MAPTMAPK1PGRHTR1A
SCHEMBL8366995 0.73 MAOB (0.57) MMP2MMP9ADAM17MAPK1MAOB
SCHEMBL3032905 0.73 ACHE (0.47) VKORC1ALOX15MAPTMAPK1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 EP disclosed
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES AG (AT) 2014-11-27 US disclosed
EP-2674161-A1 FMO3 inhibitors for treating pain Akron Molecules GmbH (AT) 2013-12-18 EP disclosed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 WO disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 US disclosed
EP-2637649-A2 COMPOUNDS AND METHODS FOR TREATING PAIN Akron Molecules GmbH (AT) 2013-09-18 EP disclosed
WO-2012062925-A2 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES GMBH (AT) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN TRPV1, ACHE, OPRL1 VKORC1 1322/4885ALOX15 207/4885MMP2 882/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 VKORC1 1322/4885ALOX15 207/4885MMP2 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.